Coulter Partners was delighted to partner recently with Azitra Inc., to secure the appointment of Mark Sampson, Ph.D. as Chief Scientific Officer. Azitra is a clinical-stage medical dermatology company addressing severe skin conditions by harnessing the microbiome and has just announced that it has closed a $14 million Series A financing, led by KdT Ventures in conjunction with existing investor Bios Partners. Connecticut Innovations and Godfrey Capital also participated in the round. Proceeds from the financing will be used to expand the management team and to advance Azitra’s medical dermatology products in the clinic. This financing brings the total raised to date to $17 million.
“Mark brings insight, experience and focused leadership to our programs and will play an instrumental role in bringing Azitra to the next level. I thank the team at Coulter Partners for their outstanding work in helping us achieve this quality appointment. We have made tremendous progress this year, and with Mark leading our technical team I am confident we will enjoy more growth and success,” said Richard Andrews, MS, President and CEO of Azitra.
Dr. Sampson most recently worked with Botanix Pharmaceuticals where he was responsible for development of the preclinical strategy and clinical development plans for new antimicrobial indications. Previously, he served as Vice President of Research and Development at Realm Therapeutics (formerly Puricore), a company developing therapeutics for dermatology and immune-mediated diseases. Dr. Sampson held prior research roles at Sterilox Technologies and Warwick International Ltd. He earned an undergraduate degree and Ph.D. degree in Microbiology/Biochemistry from the University of Aberdeen, UK.
“I am very excited to join Azitra at this important stage of the company’s growth as additional products begin to enter clinical trials,” said Dr. Sampson. “Azitra’s unique approach to leveraging the microbiome to treat adverse skin conditions holds great promise. I look forward to continuing to build the team and advance these programs focused on exciting potential new treatments for serious skin conditions.”
Azitra, Inc. is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its pharmaceutical programs to treat cancer therapy associated skin rashes, targeted orphan indications and atopic dermatitis.
For more information about Azitra, please visit www.azitrainc.com
Basel Healthtech Conference 2024
25 January 2024 – 26 January 2024
Coulter Partners places Board Director at IN8bio
18 May 2023
Coulter Partners finds Chief Medical Officer for Memo Therapeutics AG
13 July 2021
Top global hires for large-cap, mid-cap and public companies
07 October 2020